| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 185.7 | 133.0 |
| Profit before tax | -40.2 | 2.6 |
| Net income | -40.8 | 2.9 |
| EPS (diluted, $ a share) | $-0.87 | $0.05 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +39.6% |
|---|---|
| Operating margin | -32.2% |
10-Q filed with the SEC, NASDAQ: MIRM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Mirum Pharmaceuticals, Inc.: key numbers
- Share price
- $91.58Close, Nov 16
- Market cap
- $5.98B
- Shares outstanding
- 65.28MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Mirum Pharmaceuticals, Inc.
All →Mirum Pharmaceuticals Director Laura Brege Sells $1.33M of Stock
Laura Brege, Director, sold 14,167 shares of Mirum Pharmaceuticals, Inc. at $94.05 to $94.74 a share (average $94.21) in 2 transactions, worth $1.33M in total on Nov 11, 2026. Shares held after the trade: 15,703 (-17.2%).
- Value
- $1.33M
- Shares
- 14,167
- Average price
- $94.21
- Role
- Director
- Holding change
- -17.2%
- Trade date
- Nov 11, 2026
Mirum Pharmaceuticals Clinical Trial Data
Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 study of brelovitug met its primary endpoint in patients with chronic hepatitis delta virus (HDV). The study showed that 59% of patients on the 300 mg weekly dose achieved the combined endpoint of virologic response and ALT normalization compared to 0% in the delayed-treatment arm. This data, alongside results from the AZURE-1 study, will form the basis of the company's U.S. registration package for brelovitug.
Mirum Pharmaceuticals CEO Christopher Peetz Sells $1.8M of Stock
Christopher Peetz, CEO, sold 20,000 shares of Mirum Pharmaceuticals, Inc. at $90.00 a share, worth $1.8M in total on Nov 4, 2026. Shares held after the trade: 206,637 (-8.8%).
- Value
- $1.8M
- Shares
- 20,000
- Price
- $90.00
- Role
- CEO
- Holding change
- -8.8%
- Trade date
- Nov 4, 2026
Mirum Pharmaceuticals Earnings Call: Key Takeaways
Mirum Pharmaceuticals delivered a strong Q3 2026, raising full-year revenue guidance to $715M-$720M while preparing for five potential regulatory submissions in early 2027.
- Call
- Nov 3, 2026, 4:30 PM ET
Mirum Pharmaceuticals Financial Results
Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7 million, driven by strong performance from LIVMARLI and Bile Acid Medicines. The company increased its full-year 2026 net product sales guidance to a range of $715 million to $720 million following the FDA approval and launch of ATEBRIOZ for FOP.
“The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 results across our late-stage rare liver portfolio. Positive results from AZURE-1 and additional data we’ll be sharing at AASLD reinforce the potential of brelovitug to become an important new treatment for chronic HDV, while EXPAND results support the potential to bring LIVMARLI to more patients living with rare cholestatic liver diseases, including biliary atresia.”
Chris Peetz, Chief Executive Officer of Mirum
Mirum Pharmaceuticals Clinical Trial Data
Mirum Pharmaceuticals announced positive results from Cohort 2 of its pivotal PROGRESS study evaluating ATEBRIOZ (zilurgisertib) in pediatric patients aged 6 to <12 with fibrodysplasia ossificans progressiva (FOP). The study met its endpoints with a significant reduction in total heterotopic ossification lesion volume and improved joint mobility compared to placebo, supporting a planned sNDA submission in the first half of 2027.